RnRMarketResearch.com adds “Pancreatitis – Pipeline Review, H1 2015“report to its research database.
The report “Pancreatitis – Pipeline Review, H1 2015” provides comprehensive information on the therapeutic development for Pancreatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatitis and special features on late-stage and discontinued projects.
Complete Report Details @ http://www.rnrmarketresearch.com/pancreatitis-pipeline-review-h1-2015-market-report.html .
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Purchase a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=382509 .
Companies discussed in this report includes: D-Pharm Ltd., Dynavax Technologies Corporation, GlaxoSmithKline plc, Pharming Group N.V.
Drugs profiles discussed in this report includes AEM-28-02, C1 esterase inhibitor, DP-b99, Drugs to Inhibit Kynurenine 3-Monooxygenase for Acute Pancreatitis, DV-1179, GSK-6288B, PZ-235, SP-20201, SUN-102.
Featured News & Press Releases:
· Jun 12, 2014: D-Pharm's DP-b99 Prevents Abnormal Neuronal Plasticity and Pathological Brain Reorganization
· Jan 14, 2014: D-Pharm Announces Recruitment of the First Patient Into Its Phase 2 Clinical Trial With DP-b99 in Acute High-Risk Pancreatitis
· Nov 21, 2013: D-Pharm starts Phase 2 Clinical Study with DP-b99 in Acute High-Risk Pancreatitis Patients
· Oct 14, 2013: D-Pharm Schedules Investigators Meeting to Discuss Protocol of Phase 2 Clinical Study of DP-b99 for Acute High-Risk Pancreatitis
Table of Contents
List of Tables